Persistent Use Higher With New Generation Beta-Blockers

This article originally appeared here.
Share this content:
Persistent Use Higher With New Generation Beta-Blockers
Persistent Use Higher With New Generation Beta-Blockers

FRIDAY, July 22, 2016 (HealthDay News) -- Persistent use of antihypertensive treatments is greater with the new generation of beta-blockers, compared to atenolol, according to a study published in the August issue of Cardiovascular Therapeutics.

Yun Jung Choi, from Hanyang University in South Korea, and colleagues analyzed persistent use of antihypertensive medications among 9,978 patients (≥18 years) with newly diagnosed hypertension in 2012. The participants were without hypertension-related complication and had initiated treatment with beta-blocker monotherapy.

The researchers found that the rate of treatment persistence was higher in the non-atenolol group (P < 0.0001), and time to treatment discontinuation was earlier in the atenolol group (P < 0.0001). Compared to atenolol, new generation beta-blockers demonstrated a lower risk of treatment discontinuation (hazard ratio [HR], 0.91), with notable improvement seen with carvedilol and nebivolol (HRs, 0.74 and 0.79, respectively). Betaxolol showed a substantially greater hazard for discontinuation versus atenolol.

"This study demonstrated meaningful improvement in treatment persistence with new generation beta-blockers compared to atenolol, with betaxolol as exception," the authors write.

Abstract
Full Text (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!




Already a member?

Sign In Now »

Drug Lookup

Browse drugs by: BrandGenericDisease

Trending Activities

All Professions



Sign up for myCME e-newsletters




More in Home

Rising Fatal Drug Overdoses Linked to Years of Life Lost

Rising Fatal Drug Overdoses Linked to Years of ...

Growth in fatal overdoses linked to increased mortality, years of life lost for non-Hispanic whites

Atherosclerotic CVD Mortality Higher in South Asians in the U.S.

Atherosclerotic CVD Mortality Higher in South Asians in ...

Most of the increased risk can be attributed to increased prevalence of known risk factors

Global Variation in Personal Health Care Access and Quality

Global Variation in Personal Health Care Access and ...

Highest performance in Iceland, lowest in Central African Republic, with variation in rate of progress